Guselkumab: Mid‐term effectiveness, drug survival, and safety in real clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Guselkumab: Mid‐term effectiveness, drug survival, and safety in real clinical practice

Published:2021-02-07 Issue:2 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Ruiz‐Villaverde Ricardo¹^ORCID,Rodriguez‐Fernandez‐Freire Lourdes²,Armario‐Hita Jose Carlos³,Pérez‐Gil Amalia⁴,Galán‐Gutiérrez Manuel⁵

Affiliation:

1. Department of Dermatology Hospital Universitario San Cecilio Granada Spain

2. Department of Dermatology Hospital Universitario Virgen del Rocio Sevilla Spain

3. Department of Dermatology Hospital Universitario Puerto Real Cádiz Spain

4. Department of Dermatology Hospital Universitario Virgen de Valme Sevilla Spain

5. Department of Dermatology Hospital Universitario Reina Sofía Córdoba Spain

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14798

Reference11 articles.

1. Guselkumab: Short‐term effectiveness and safety in real clinical practice

2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

3. Tremfya Data Sheet.Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)(2020).

4. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44‐week real‐life experience;Megna M;J Dermatolog Treat,2020

5. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden;Journal of the European Academy of Dermatology and Venereology;2024-08-02

2. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

3. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G‐EPOSS study;Journal of the European Academy of Dermatology and Venereology;2024-04-11

4. Real‐life data over 36 weeks of guselkumab treatment in psoriasis patients: A single‐center study from Turkey;Journal of Cosmetic Dermatology;2024-03-15

5. Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort Study;Journal of Investigative Dermatology;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3